Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK ‘Needs To Be On EU’s API White List’ Post-Brexit

Executive Summary

The UK pharmaceutical industry is concerned about potential barriers to trade that might arise with the EU post-Brexit, especially if co-operation mechanisms such as mutual recognition agreements are not in place by the time the UK leaves. API manufacturers have specific worries, but there won’t be answers for some time.

You may also be interested in...



Change And More Change: That’s What Brexit Means For Drug Companies

The EU medicines network has issued a long list of changes that drug companies with activities in the UK will have to make if they are to continue to be located from a regulatory standpoint in the European Economic Area following Brexit. Aspects affected include the location of orphan designation holders, qualified persons for pharmacovigilance, companies’ manufacturing and batch release sites and maintenance of SME status.

UK Not Planning To Add to Regulatory Burden for Life Science Industry Post-Brexit

The UK seemingly has no intention of imposing new regulatory requirements on life science companies after the country leaves the EU. That’s all well and good, but companies in the UK looking to continue doing business in the EU are worried they will face significant trade barriers post-Brexit. Everything will depend on the outcome of soon-to-start exit negotiations.

Ruffled feathers and interim measures: API rules applied

It wasn't quite an international incident, but this year's introduction of new EU rules for certifying the quality of imported active pharmaceutical ingredients (APIs) certainly ruffled many feathers among regulators in the world's major API supply markets.

Topics

UsernamePublicRestriction

Register

PS120141

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel